Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...
manilatimes17m
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
DURIPANC is an investigator-initiated, exploratory, open-label, single-center study in the Netherlands at the Erasmus Medical ...
Scientists find promising pancreatic cancer leads
Pancreatic cancer kills three in four people within the first year. But new research is offering hope to people in years to come.As few as one in ten people survive pancreatic cancer five years after ...
wglt15m
Jim Edgar hopes to beat pancreatic cancer: 'But to be very truthful, if it ended tomorrow, I've had a great life.'
The former Illinois governor has been undergoing chemotherapy after a diagnosis last month, he told the Sun-Times. “I’m ...
Genetic testing for cancer should be the norm now, experts say. Here’s when to request it.
Testing is recommended for those with personal and family histories of several types of cancer — including pancreatic and ...
manilatimes58m
Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit
Dr. Newman will deliver a scientific presentation on Tuesday, March 4, 2025, titled, "Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity.” In this ...